{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=zanzalintinib", "query": { "intervention": "zanzalintinib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 38, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=zanzalintinib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T21:49:34.103Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06926634", "title": "Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Neuroendocrine Neoplasms" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2025-12-09", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-09-14T21:49:34.103Z", "location_count": 2, "location_summary": "Rochester, Minnesota • St Louis, Missouri", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06926634" }, { "nct_id": "NCT06943755", "title": "Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pancreatic Neuroendocrine Tumor (pNET)", "Extra-Pancreatic Neuroendocrine Tumor (epNET)" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 440, "start_date": "2025-07-21", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-14T21:49:34.103Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06943755" }, { "nct_id": "NCT07049926", "title": "Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Belzutifan", "type": "DRUG" }, { "name": "Zanzalintinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 140, "start_date": "2025-07-20", "completion_date": "2031-10-26", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-14T21:49:34.103Z", "location_count": 7, "location_summary": "San Francisco, California • Mineola, New York • New York, New York + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Mineola", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07049926" }, { "nct_id": "NCT07620574", "title": "Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer", "Renal Cell Carcinoma (RCC)", "Pancreatic Neuroendocrine Tumors (pNET)", "Extra-Pancreatic NET (epNET)", "Hepatocellular Carcinoma (HCC)", "Differentiated Thyroid Cancer (DTC)", "Non-Clear Cell Renal Cell Carcinoma (nccRCC)", "Colorectal Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Zanzalintinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5000, "start_date": "2026-07-30", "completion_date": "2030-05-31", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-14T21:49:34.103Z", "location_count": 2, "location_summary": "Bay Shore, New York • Kettering, Ohio", "locations": [ { "city": "Bay Shore", "state": "New York" }, { "city": "Kettering", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07620574" }, { "nct_id": "NCT06968988", "title": "Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Soft-tissue Sarcoma" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-01-05", "completion_date": "2034-01-31", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-14T21:49:34.103Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06968988" }, { "nct_id": "NCT06568562", "title": "XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "XL092", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 32, "start_date": "2024-12-09", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-14T21:49:34.103Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06568562" }, { "nct_id": "NCT07193550", "title": "A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Sarcomas" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-12-05", "completion_date": "2031-10-31", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-09-14T21:49:34.103Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07193550" }, { "nct_id": "NCT07470489", "title": "Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Thyroid Cancer" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Zanzalintinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2026-09-30", "completion_date": "2032-09-01", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-14T21:49:34.103Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07470489" }, { "nct_id": "NCT06959641", "title": "XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Differentiated Thyroid Gland Carcinoma", "Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma", "Locally Advanced Thyroid Gland Follicular Carcinoma", "Locally Advanced Thyroid Gland Oncocytic Carcinoma", "Locally Advanced Thyroid Gland Papillary Carcinoma", "Metastatic Differentiated Thyroid Gland Carcinoma", "Metastatic Poorly Differentiated Thyroid Gland Carcinoma", "Metastatic Thyroid Gland Follicular Carcinoma", "Metastatic Thyroid Gland Oncocytic Carcinoma", "Metastatic Thyroid Gland Papillary Carcinoma", "Refractory Differentiated Thyroid Gland Carcinoma", "Refractory Poorly Differentiated Thyroid Gland Carcinoma", "Refractory Thyroid Gland Follicular Carcinoma", "Refractory Thyroid Gland Oncocytic Carcinoma", "Refractory Thyroid Gland Papillary Carcinoma", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage III Thyroid Gland Follicular Carcinoma AJCC v8", "Stage III Thyroid Gland Papillary Carcinoma AJCC v8", "Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage IV Thyroid Gland Follicular Carcinoma AJCC v8", "Stage IV Thyroid Gland Papillary Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" }, { "name": "Zanzalintinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Jochen Lorch", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2025-06-06", "completion_date": "2030-09-11", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-09-14T21:49:34.103Z", "location_count": 2, "location_summary": "Torrance, California • Chicago, Illinois", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06959641" }, { "nct_id": "NCT07042919", "title": "Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Hepatocellular Carcinoma", "Cirrhosis", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Zanzalintinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Devalingam Mahalingam", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2026-03-30", "completion_date": "2031-03-04", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-09-14T21:49:34.103Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07042919" } ] }